Search

Search Constraints

You searched for: Author/Creator Kosiborod, Mikhail N

Search Results

1. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. (29th November 2021)

2. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Issue 1 (January 2022)

3. Dapagliflozin for heart failure according to body mass index: the DELIVER trial . (27th August 2022)

4. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 9 (September 2021)

6. Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). (21st August 2020)

7. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. (27th August 2021)

8. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. (28th March 2020)

9. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial. Issue 12 (December 2022)

10. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. (18th October 2022)